N'ọnwa Machị afọ 2017, FDA kwadoro ocrelizumab, anti-CD20 monoclonal antibody, dị ka ọgwụgwọ maka RRMS, na ihe achọrọ maka ọtụtụ ule nke Phase IV. Na RRMS, ha na-ebelata ọnụ ọgụgụ nke ọgụ. Ndị a bụ interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, ocrelizumab, siponimod, na cladribine. N'ọnwa Machị afọ 2017, FDA kwadoro ocrelizumab, anti-CD20 monoclonal antibody, dị ka ọgwụgwọ maka RRMS, na ihe achọrọ maka ọtụtụ ule nke Phase IV. Na RRMS, ha na-ebelata ọnụ ọgụgụ nke ọgụ. Ndị a bụ interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, mitoxantrone, mitoxantrone, natalizumab, natalizumab, natalizumab, natalizumab, natalizumab
interferon beta-1a